Moderna has submitted regulatory applications for mRNA‑1010, its seasonal influenza vaccine built on mRNA technology, to regulators in the U.S., Europe, Canada and Australia. The company reported phase 3 data showing modest efficacy improvements versus standard vaccines in people aged 50 and older and positioned the shot as a strategic revenue driver as COVID and RSV revenues wane. CEO Stéphane Bancel framed the filing as a core step to return Moderna to growth by 2027.